- Document Number:
20240277611
- Appl. No:
18/566854
- Application Filed:
June 01, 2022
- نبذة مختصرة :
The present disclosure relates to a composition comprising: (a) about 5.0% w/w to about 40.0% w/w of a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, and (b) about 0.25% w/w to about 5.00% w/w of a viscosity modifier, and to a method of manufacturing the composition. The present disclosure also relates to the uses of the composition and methods for preventing or treating mastitis.
- Assignees:
Norbrook Laboratories Limited (Newry, GB)
- Claim:
1. A composition comprising: (a) about 5.0% w/w to about 40.0% w/w of a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer; and (b) about 0.25% w/w to about 5.00% w/w of a viscosity modifier.
- Claim:
2. The composition according to claim 1, wherein the viscosity modifier is selected from a poly(acrylic acid), a polyvinylpyrrolidone, a colloidal silica, an alginate, a microcrystalline cellulose, and a mixture of a microcrystalline cellulose and a carboxymethylcellulose.
- Claim:
3. The composition according to claim 1, wherein the viscosity modifier is a poly(acrylic acid).
- Claim:
4. The composition according to claim 3, wherein the poly(acrylic acid) is a polymer of acrylic acid cross-linked with a polyalkenyl polyether.
- Claim:
5. The composition according to claim 3, wherein the poly(acrylic acid) is a cross-linked with an allyl ether of propylene, an allyl ether of sucrose or an allyl ether of pentaerythritol.
- Claim:
6. The composition according to claim 3, wherein the poly(acrylic acid) is a homopolymer of acrylic acid or a copolymer of acrylic acid.
- Claim:
7. The composition according to claim 3, wherein the composition comprises a total amount of about 0.75% w/w to about 2.00% w/w of the poly(acrylic acid).
- Claim:
8. The composition according to claim 1, wherein the composition comprises about 15.0% w/w to about 25.0% w/w of the polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer.
- Claim:
9. The composition according to claim 1, wherein the polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer has a weight average molecular weight of from about 50000 to about 250000 g·mol−1.
- Claim:
10. The composition according to claim 1, which does not comprise bismuth.
- Claim:
11. The composition according to claim 1, further comprising a pH adjuster.
- Claim:
12. The composition according to claim 11, wherein the pH adjuster is a buffer.
- Claim:
13. The composition according to claim 11, wherein the pH adjuster is a base.
- Claim:
14. The composition according to claim 1, further comprising a total amount of about 0.1% w/w to about 2.5% w/w of a tonicity modifier.
- Claim:
15. The composition according to claim 1, further comprising a cosolvent.
- Claim:
16. The composition according to claim 1, further comprising a therapeutic agent.
- Claim:
17. The composition according to claim 1, further comprising water.
- Claim:
18. (canceled)
- Claim:
19. (canceled)
- Claim:
20. A method of treating or preventing mastitis comprising administering a composition according to claim 1 to a mammary gland of an animal.
- Claim:
21. A kit of parts comprising (a) the composition according to claim 1 together with instructions for simultaneous, concurrent, separate or sequential use in combination with (b) a therapeutic agent.
- Claim:
22. (canceled)
- Claim:
23. (canceled)
- Claim:
24. (canceled)
- Claim:
25. A method of manufacturing a composition as defined in claim 1, wherein the method comprises mixing a suspension of a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer with a viscosity modifier and optionally a colouring agent.
- Current International Class:
61; 61; 61; 61
- الرقم المعرف:
edspap.20240277611
Processing Request
No Comments.